Tecan remains on growth track

Financial results for the full-year 2019 – Highlights

• Sales of CHF 636.8 million (2018: CHF 593.8 million)
  • Full-year growth of 8.0% in local currencies and 7.2% in Swiss francs
  • Full-year organic growth of 6.0% in local currencies and 5.3% in Swiss francs
  • Double-digit sales growth in the Life Sciences Business
  • Growth trend continues in the second half of the year
• Full-year operating profit before depreciation and amortization (EBITDA) of CHF 122.8 million (2018: CHF 110.3 million)
  • Increase in reported EBITDA margin to 19.3% (2018: 18.6%), including all acquisition-related costs
• Reported full-year net profit of CHF 73.2 million (2018: CHF 70.7 million) 
  • Net profit margin 11.5%, including all acquisition-related costs (2018: 11.9%)
  • Earnings per share rose to CHF 6.18 (2018: CHF 6.02)

Operating highlights 2019 and other important information

• Launch of DreamPrep NGS, a fully automated sample preparation solution for next-generation sequencing (NGS)
• New offers and continued focus on recurring sales generated from reagents and consumables in key applications
• Launch of Spark Cyto reader platform with imaging capabilities for applications in cell biology
• Several launches of new instruments in the Partnering Business, good progress made with important development projects
• Acquisition of a supplier of key parts successfully completed
• Increase in the dividend proposed from CHF 2.10 to CHF 2.20 per share

Outlook 2020

• Full-year sales are again forecast to increase in the mid- to high single-digit percentage range in local currencies
• Reported EBITDA margin expected to expand to around 19.6% of sales

Männedorf, Switzerland, 17 March 2020 – The Tecan Group (SIX Swiss Exchange: TECN) remains on its growth track and can look back on a very successful business year. Tecan once again posted a substantial increase in sales, driven by strong growth in the Life Sciences Business. The company was also able to improve net profit despite the inclusion of acquisition-related costs.